ACET vs NTLA vs EDIT vs FATE

For growth investors, Editas Medicine, Inc.

(EDIT) is the stronger pick with 25. 4% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Adicet Bio, Inc. (ACET) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Adicet Bio, Inc.

(ACET) delivered a total return of -31. 6%, compared to -97. 7% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: FATE returned +15. 7% versus ACET's -92. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fate Therapeutics, Inc.

(FATE) is the lower-risk stock at 1. 93β versus Editas Medicine, Inc. 's 2. 52β — meaning EDIT is approximately 31% more volatile than FATE relative to the S&P 500. On balance sheet safety, Adicet Bio, Inc. (ACET) carries a lower debt/equity ratio of 9% versus 3% for Editas Medicine, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Editas Medicine, Inc.

(EDIT) is pulling ahead at 25. 4% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Editas Medicine, Inc. grew EPS 37. 5% year-over-year, compared to 20. 3% for Adicet Bio, Inc.. Over a 3-year CAGR, EDIT leads at 27. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Adicet Bio, Inc.

(ACET) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACET leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — EDIT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Fate Therapeutics, Inc.

(FATE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Adicet Bio, Inc. (ACET) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FATE: +15. 7%, ACET: -92. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACET is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock; EDIT is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.